trending Market Intelligence /marketintelligence/en/news-insights/trending/Bi_RZyFzzi7g_LaVzq_pSw2 content esgSubNav
In This List

Pfizer, eFFECTOR enter licensing, collaboration deal to develop cancer therapies

Blog

Insight Weekly: M&A players predict 2023 activity; SPAC IPOs dip; 2022 capacity retirements up

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share


Pfizer, eFFECTOR enter licensing, collaboration deal to develop cancer therapies

Pfizer Inc. has joined with San Diego-based private biotech eFFECTOR Therapeutics Inc. to develop small-molecule inhibitors of a certain protein that is activated in a number of human cancers.

The collaboration will focus on the development of small-molecule inhibitors of eukaryotic initiation factor 4E, a protein that resists certain cancer treatments and is linked to poor prediction of the disease.

Under the exclusive worldwide license and collaboration agreement, Pfizer will pay eFFECTOR $15 million upfront and up to an additional $492 million in potential development and sales milestone payments.

Additionally, eFFECTOR will receive royalties on sales of any products from the program that reaches the commercialization stage.